Literature DB >> 18406327

Deletion of histone deacetylase 3 reveals critical roles in S phase progression and DNA damage control.

Srividya Bhaskara1, Brenda J Chyla, Joseph M Amann, Sarah K Knutson, David Cortez, Zu-Wen Sun, Scott W Hiebert.   

Abstract

Histone deacetylases (HDACs) are enzymes that modify key residues in histones to regulate chromatin architecture, and they play a vital role in cell survival, cell-cycle progression, and tumorigenesis. To understand the function of Hdac3, a critical component of the N-CoR/SMRT repression complex, a conditional allele of Hdac3 was engineered. Cre-recombinase-mediated inactivation of Hdac3 led to a delay in cell-cycle progression, cell-cycle-dependent DNA damage, and apoptosis in mouse embryonic fibroblasts (MEFs). While no overt defects in mitosis were observed in Hdac3-/- MEFs, including normal H3Ser10 phosphorylation, DNA damage was observed in Hdac3-/- interphase cells, which appears to be associated with defective DNA double-strand break repair. Moreover, we noted that Hdac3-/- MEFs were protected from DNA damage when quiescent, which may provide a mechanistic basis for the action of HDAC inhibitors on cycling tumor cells.

Entities:  

Mesh:

Substances:

Year:  2008        PMID: 18406327      PMCID: PMC2373760          DOI: 10.1016/j.molcel.2008.02.030

Source DB:  PubMed          Journal:  Mol Cell        ISSN: 1097-2765            Impact factor:   17.970


  57 in total

1.  N-terminal region, C-terminal region, nuclear export signal, and deacetylation activity of histone deacetylase-3 are essential for the viability of the DT40 chicken B cell line.

Authors:  Y Takami; T Nakayama
Journal:  J Biol Chem       Date:  2000-05-26       Impact factor: 5.157

2.  Expression of the AML-1 oncogene shortens the G(1) phase of the cell cycle.

Authors:  D K Strom; J Nip; J J Westendorf; B Linggi; B Lutterbach; J R Downing; N Lenny; S W Hiebert
Journal:  J Biol Chem       Date:  2000-02-04       Impact factor: 5.157

3.  Clinical experience with intravenous and oral formulations of the novel histone deacetylase inhibitor suberoylanilide hydroxamic acid in patients with advanced hematologic malignancies.

Authors:  Owen A O'Connor; Mark L Heaney; Lawrence Schwartz; Stacie Richardson; Robert Willim; Barbara MacGregor-Cortelli; Tracey Curly; Craig Moskowitz; Carol Portlock; Steven Horwitz; Andrew D Zelenetz; Stanley Frankel; Victoria Richon; Paul Marks; William K Kelly
Journal:  J Clin Oncol       Date:  2005-12-05       Impact factor: 44.544

Review 4.  Acute myeloid leukemia: therapeutic impact of epigenetic drugs.

Authors:  Lucia Altucci; Nicole Clarke; Angela Nebbioso; Annamaria Scognamiglio; Hinrich Gronemeyer
Journal:  Int J Biochem Cell Biol       Date:  2005-09       Impact factor: 5.085

5.  Modifications of H3 and H4 during chromatin replication, nucleosome assembly, and histone exchange.

Authors:  Laura J Benson; Yongli Gu; Tatyana Yakovleva; Kevin Tong; Courtney Barrows; Christine L Strack; Richard G Cook; Craig A Mizzen; Anthony T Annunziato
Journal:  J Biol Chem       Date:  2006-02-07       Impact factor: 5.157

6.  Histone deacetylase inhibitors (HDI) cause DNA damage in leukemia cells: a mechanism for leukemia-specific HDI-dependent apoptosis?

Authors:  Terry J Gaymes; Rose Ann Padua; Marika Pla; Stephen Orr; Nader Omidvar; Christine Chomienne; Ghulam J Mufti; Feyruz V Rassool
Journal:  Mol Cancer Res       Date:  2006-08       Impact factor: 5.852

7.  Nuclear levels and patterns of histone H3 modification and HP1 proteins after inhibition of histone deacetylases.

Authors:  Eva Bártová; Jirí Pacherník; Andrea Harnicarová; Ales Kovarík; Martina Kovaríková; Jirina Hofmanová; Magdalena Skalníková; Michal Kozubek; Stanislav Kozubek
Journal:  J Cell Sci       Date:  2005-11-01       Impact factor: 5.285

8.  Chromatin relaxation in response to DNA double-strand breaks is modulated by a novel ATM- and KAP-1 dependent pathway.

Authors:  Yael Ziv; Dana Bielopolski; Yaron Galanty; Claudia Lukas; Yoichi Taya; David C Schultz; Jiri Lukas; Simon Bekker-Jensen; Jiri Bartek; Yosef Shiloh
Journal:  Nat Cell Biol       Date:  2006-07-23       Impact factor: 28.824

9.  Histone deacetylase 3 (HDAC3) and other class I HDACs regulate colon cell maturation and p21 expression and are deregulated in human colon cancer.

Authors:  Andrew J Wilson; Do-Sun Byun; Natalia Popova; Lucas B Murray; Kaitlin L'Italien; Yoshihiro Sowa; Diego Arango; Anna Velcich; Leonard H Augenlicht; John M Mariadason
Journal:  J Biol Chem       Date:  2006-03-13       Impact factor: 5.157

Review 10.  Modulation of cellular radiation responses by histone deacetylase inhibitors.

Authors:  T C Karagiannis; A El-Osta
Journal:  Oncogene       Date:  2006-02-06       Impact factor: 9.867

View more
  177 in total

Review 1.  Histone deacetylase (HDAC) inhibition as a novel treatment for diabetes mellitus.

Authors:  Dan P Christensen; Mattias Dahllöf; Morten Lundh; Daniel N Rasmussen; Mette D Nielsen; Nils Billestrup; Lars G Grunnet; Thomas Mandrup-Poulsen
Journal:  Mol Med       Date:  2011-01-25       Impact factor: 6.354

Review 2.  Hdac-mediated control of endochondral and intramembranous ossification.

Authors:  Elizabeth W Bradley; Meghan E McGee-Lawrence; Jennifer J Westendorf
Journal:  Crit Rev Eukaryot Gene Expr       Date:  2011       Impact factor: 1.807

3.  HDAC5 is required for maintenance of pericentric heterochromatin, and controls cell-cycle progression and survival of human cancer cells.

Authors:  P Peixoto; V Castronovo; N Matheus; C Polese; O Peulen; A Gonzalez; M Boxus; E Verdin; M Thiry; F Dequiedt; D Mottet
Journal:  Cell Death Differ       Date:  2012-02-03       Impact factor: 15.828

Review 4.  Multiple roles of class I HDACs in proliferation, differentiation, and development.

Authors:  Nina Reichert; Mohamed-Amin Choukrallah; Patrick Matthias
Journal:  Cell Mol Life Sci       Date:  2012-07       Impact factor: 9.261

5.  Overlapping functions of Hdac1 and Hdac2 in cell cycle regulation and haematopoiesis.

Authors:  Roel H Wilting; Eva Yanover; Marinus R Heideman; Heinz Jacobs; James Horner; Jaco van der Torre; Ronald A DePinho; Jan-Hermen Dannenberg
Journal:  EMBO J       Date:  2010-06-22       Impact factor: 11.598

6.  Histone deacetylase 3 regulates smooth muscle differentiation in neural crest cells and development of the cardiac outflow tract.

Authors:  Nikhil Singh; Chinmay M Trivedi; MinMin Lu; Shannon E Mullican; Mitchell A Lazar; Jonathan A Epstein
Journal:  Circ Res       Date:  2011-09-29       Impact factor: 17.367

7.  Hdac3 is essential for the maintenance of chromatin structure and genome stability.

Authors:  Srividya Bhaskara; Sarah K Knutson; Guochun Jiang; Mahesh B Chandrasekharan; Andrew J Wilson; Siyuan Zheng; Ashwini Yenamandra; Kimberly Locke; Jia-Ling Yuan; Alyssa R Bonine-Summers; Christina E Wells; Jonathan F Kaiser; M Kay Washington; Zhongming Zhao; Florence F Wagner; Zu-Wen Sun; Fen Xia; Edward B Holson; Dineo Khabele; Scott W Hiebert
Journal:  Cancer Cell       Date:  2010-11-16       Impact factor: 31.743

Review 8.  Histone Deacetylases in Bone Development and Skeletal Disorders.

Authors:  Elizabeth W Bradley; Lomeli R Carpio; Andre J van Wijnen; Meghan E McGee-Lawrence; Jennifer J Westendorf
Journal:  Physiol Rev       Date:  2015-10       Impact factor: 37.312

9.  Histone deacetylase 3 suppresses Erk phosphorylation and matrix metalloproteinase (Mmp)-13 activity in chondrocytes.

Authors:  Lomeli R Carpio; Elizabeth W Bradley; Jennifer J Westendorf
Journal:  Connect Tissue Res       Date:  2016-09-23       Impact factor: 3.417

10.  Epstein-Barr virus episome stability is coupled to a delay in replication timing.

Authors:  Jing Zhou; Andrew R Snyder; Paul M Lieberman
Journal:  J Virol       Date:  2008-12-10       Impact factor: 5.103

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.